These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34448695)

  • 1. Lower response to denosumab in diabetes patients on hemodialysis.
    Han SH; Jo HA; Han KH; Han SY
    Clin Nephrol; 2022 Feb; 97(2):70-77. PubMed ID: 34448695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.
    Hiramatsu R; Ubara Y; Sawa N; Sakai A
    Nephrol Dial Transplant; 2021 Sep; 36(10):1900-1907. PubMed ID: 33544866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of denosumab on bone mineral density and turnover markers in patients undergoing hemodialysis.
    Kato K; Yaginuma T; Kobayashi A; Nakashima A; Ohkido I; Yokoo T
    J Bone Miner Metab; 2024 Mar; 42(2):264-270. PubMed ID: 38512458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
    Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
    Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
    Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
    Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients.
    Sit D; Kadiroglu AK; Kayabasi H; Atay AE; Yilmaz Z; Yilmaz ME
    Adv Ther; 2007; 24(5):987-95. PubMed ID: 18029324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab for dialysis patients with osteoporosis: A cohort study.
    Kunizawa K; Hiramatsu R; Hoshino J; Mizuno H; Ozawa Y; Sekine A; Kawada M; Sumida K; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Ubara Y; Takaichi K
    Sci Rep; 2020 Feb; 10(1):2496. PubMed ID: 32051451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
    Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
    J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Power of Bone Turnover Biomarkers to Estimate Bone Mineral Density after Kidney Transplantation with or without Denosumab: A post hoc Analysis of the POSTOP Study.
    Heimgartner N; Graf N; Frey D; Saleh L; Wüthrich RP; Bonani M
    Kidney Blood Press Res; 2020; 45(5):758-767. PubMed ID: 32998144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
    Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
    Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial.
    Iseri K; Watanabe M; Yoshikawa H; Mitsui H; Endo T; Yamamoto Y; Iyoda M; Ryu K; Inaba T; Shibata T
    J Bone Miner Res; 2019 Jun; 34(6):1014-1024. PubMed ID: 30690785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients.
    Hori M; Yasuda K; Takahashi H; Kondo C; Shirasawa Y; Ishimaru Y; Sekiya Y; Morozumi K; Maruyama S
    Sci Rep; 2022 May; 12(1):7781. PubMed ID: 35546172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
    Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
    Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis.
    Thongprayoon C; Acharya P; Aeddula NR; Torres-Ortiz A; Bathini T; Sharma K; Ungprasert P; Watthanasuntorn K; Suarez MLG; Salim SA; Kaewput W; Chenbhanich J; Mao MA; Cheungpasitporn W
    Arch Osteoporos; 2019 Mar; 14(1):35. PubMed ID: 30852679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.